Inactive Disease and Remission in Childhood-Onset Systemic Lupus Erythematosus

Imagem de Miniatura
Arquivos
art_SILVA_Inactive_Disease_and_Remission_in_Childhood_Onset_Systemic_2012.PDF (113.98 KB)
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
MINA, Rina
KLEIN-GITELMAN, Marisa S.
RAVELLI, Angelo
BERESFORD, Michael W.
AVCIN, Tadej
ESPADA, Graciela
EBERHARD, B. Anne
SCHANBERG, Laura E.
O'NEIL, Kathleen M.
Citação
ARTHRITIS CARE & RESEARCH, v.64, n.5, p.683-693, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective. To define inactive disease (ID) and clinical remission (CR) and to delineate variables that can be used to measure ID/CR in childhood-onset systemic lupus erythematosus (cSLE). Methods. Delphi questionnaires were sent to an international group of pediatric rheumatologists. Respondents provided information about variables to be used in future algorithms to measure ID/CR. The usefulness of these variables was assessed in 35 children with ID and 31 children with minimally active lupus (MAL). Results. While ID reflects cSLE status at a specific point in time, CR requires the presence of ID for >6 months and considers treatment. There was consensus that patients in ID/CR can have <2 mild nonlimiting symptoms (i.e., fatigue, arthralgia, headaches, or myalgia) but not Raynaud's phenomenon, chest pain, or objective physical signs of cSLE; antinuclear antibody positivity and erythrocyte sedimentation rate elevation can be present. Complete blood count, renal function testing, and complement C3 all must be within the normal range. Based on consensus, only damage-related laboratory or clinical findings of cSLE are permissible with ID. The above parameters were suitable to differentiate children with ID/CR from those with MAL (area under the receiver operating characteristic curve >0.85). Disease activity scores with or without the physician global assessment of disease activity and patient symptoms were well suited to differentiate children with ID from those with MAL. Conclusion. Consensus has been reached on common definitions of ID/CR with cSLE and relevant patient characteristics with ID/CR. Further studies must assess the usefulness of the data-driven candidate criteria for ID in cSLE.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/4470
Referências
  1. Bertolaccini ML, 2011, LUPUS, V20, P191, DOI 10.1177/0961203310397082
  2. Boers Maarten, 2010, Bull NYU Hosp Jt Dis, V68, P140
  3. Boers M, 1998, J RHEUMATOL, V25, P198
  4. Bruce IN, 2010, CURR OPIN RHEUMATOL, V22, P273, DOI 10.1097/BOR.0b013e3283374e78
  5. Brunner HI, 2008, ARTHRITIS RHEUM, V58, P556, DOI 10.1002/art.23204
  6. Brunner HI, 2011, ARTHRIT CARE RES, V63, P1213, DOI 10.1002/acr.20507
  7. Brunner HI, 1999, ARTHRITIS RHEUM, V42, P1354, DOI 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4
  8. Brunner HI, 2010, ARTHRIT CARE RES, V62, P811, DOI 10.1002/acr.20126
  9. Cheung K L, 2003, Minerva Chir, V58, P297
  10. Chung EK, 2002, AM J HUM GENET, V71, P823, DOI 10.1086/342777
  11. Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures, 2006, ARTHRITIS RHEUM, V55, P348
  12. Delbecq A. L., 1975, GROUP TECHNIQUES PRO
  13. Eyer-Silva WA, 2002, AIDS, V16, P2367, DOI 10.1097/00002030-200211220-00031
  14. Felson DT, 2011, ARTHRITIS RHEUM-US, V63, P573, DOI 10.1002/art.30129
  15. Galambos J., 1996, BONFERRONI TYPE INEQ
  16. HANLEY JA, 1982, RADIOLOGY, V143, P29
  17. Hiraki LT, 2008, J PEDIATR, V152, P550, DOI 10.1016/j.jpeds.2007.09.019
  18. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  19. Kasitanon N, 2006, MEDICINE, V85, P147, DOI 10.1097/01.md.0000227709.70133.f7
  20. Klein-Gitelman M, 2002, RHEUM DIS CLIN N AM, V28, P561, DOI 10.1016/S0889-857X(02)00015-7
  21. LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
  22. Lovell DJ, 2011, ARTHRIT CARE RES, V63, P10, DOI 10.1002/acr.20348
  23. Pierangeli SS, 2011, LUPUS, V20, P182, DOI 10.1177/0961203310395055
  24. Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
  25. Ruperto N, 2006, ARTHRIT RHEUM-ARTHR, V55, P355, DOI 10.1002/art.22002
  26. Ruperto N, 2004, CURR OPIN RHEUMATOL, V16, P566, DOI 10.1097/01.bor.0000130286.54383.ea
  27. Shtatland ES, 1998, P LOGISTIC SUGI 98 P, P1194
  28. Urowitz MB, 2005, J RHEUMATOL, V32, P1467
  29. Wallace CA, 2011, ARTHRIT CARE RES, V63, P929, DOI 10.1002/acr.20497
  30. Wallace CA, 2004, J RHEUMATOL, V31, P2290
  31. Yang Y, 2007, AM J HUM GENET, V80, P1037, DOI 10.1086/518257
  32. Yang Y, 2004, CURR DIRECT AUTOIMMU, V7, P98

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/36